Pimozide

Research use only, not for human use.

Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor.

Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor, also is an inhbitor of STAT5; also is a hERG blocker, inhibits USP1/UAF1 noncompetitively with Ki of 0.5 uM; displays selectivity against a number of deubiquitinases, deSUMOylase, and cysteine proteases.(In Vitro):Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively; also has affinity at α1-adrenoceptor and 5-HT1A, with Kis of 39 nM and 310 nM, respectively. Pimozide acts as an inhibitor of STAT3. Pimozide (0-15 μM) shows inhibitory of the proliferation of U2OS cells, with IC50 value at 24, 48, and 72 h of 22.16 ± 2.54, 17.49 ± 1.14 and 13.78 ± 0.34 μM, respectively. Pimozide (10 μM) inhibits the colony- and sphere-forming abilities of osteosarcoma cells. Pimozide (15 μM) induces G0/G1 phase cell cycle arrest, suppresses the extracellular signal-regulated kinase (Erk) signaling to inhibit cell viability, and produces ROS generation through inhibiting antioxidant enzyme gene catalase expression in osteosarcoma cells. Pimozide acts as an inhibitor of STAT5. Pimozide reduces the expression of endogenous STAT5 target genes, and decreases STAT5 tyrosine phosphorylation.

Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively; also has affinity at α1-adrenoceptor and 5-HT1A, with Kis of 39 nM and 310 nM, respectively. Pimozide acts as an inhibitor of STAT3. Pimozide (0-15 μM) shows inhibitory of the proliferation of U2OS cells, with IC50 value at 24, 48, and 72 h of 22.16 ± 2.54, 17.49 ± 1.14 and 13.78 ± 0.34 μM, respectively. Pimozide (10 μM) inhibits the colony- and sphere-forming abilities of osteosarcoma cells. Pimozide (15 μM) induces G0/G1 phase cell cycle arrest, suppresses the extracellular signal-regulated kinase (Erk) signaling to inhibit cell viability, and produces ROS generation through inhibiting antioxidant enzyme gene catalase expression in osteosarcoma cells. Pimozide acts as an inhibitor of STAT5. Pimozide reduces the expression of endogenous STAT5 target genes, and decreases STAT5 tyrosine phosphorylation.

——

NSC 170984 | Orap | R 6238

JAK/STAT Signaling

STAT

D2|PotassiumChannel

Neurological Disease

——

2062-78-4

461.56

C28H29F2N3O

>98% (HPLC)

DMSO: 10 mM （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C1N(C2CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)C5=CC=CC=C5N1

1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one

(-20℃)

With Ice Pack

≥ 2 years